i
FDA PCAC Update (July 23–24, 2026):

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 8-6-1 to recommend BPC-157 for inclusion on the Section 503A Bulks List, which would allow compounding pharmacies to produce it. This is an advisory recommendation only — the FDA has not yet issued a final ruling. The substance remains investigational and is not FDA-approved for any therapeutic indication.

Tendon • Ligament • Muscle • Bone • Wounds • Gut

BPC-157

An investigational repair peptide that has produced unusually broad healing effects across tendon, ligament, muscle, bone, wounds, and gastrointestinal tissue in experimental models.

The reason BPC-157 has attracted so much attention is not simply because it is labeled a “recovery peptide.” Researchers have repeatedly injured specific tissues and then measured whether those tissues actually healed differently.

In animal studies, the answer has often been yes: stronger repaired tendons, improved ligament biomechanics, restored muscle function, improved bone-defect healing, better collagen organization, improved blood-vessel development, and accelerated wound repair.

Tendon Repair Ligament Healing Muscle Recovery Bone Healing Wound Repair GI Protection

What Is BPC-157?

A 15-amino-acid peptide investigated across multiple forms of tissue injury

BPC-157 is a synthetic pentadecapeptide made of 15 amino acids.

What makes it interesting is the range of tissues in which researchers have observed repair-related effects.

Rather than acting as a simple pain reliever, the research around BPC-157 focuses on processes involved in rebuilding damaged tissue: fibroblast movement, collagen formation, blood-vessel signaling, cellular survival, extracellular-matrix organization, and tissue remodeling.

15 Amino Acids Small peptide structure
Connective Tissue Tendon & ligament models
Musculoskeletal Muscle & bone research
GI Biology Gastric & intestinal research

BPC-157 is interesting because the experimental question has often been simple: injure the tissue, treat it, and measure whether it becomes structurally and functionally stronger.

Where Has BPC-157 Shown Healing Effects?

The strongest evidence is preclinical—but the range of tissues studied is unusually broad

Tendons

Achilles-tendon models are among the best-known areas of BPC-157 research.

  • Improved load-to-failure strength
  • Improved tendon elasticity
  • Better collagen organization
  • Improved fibroblast formation
  • Improved functional walking scores
  • Smaller tendon defects during healing

Ligaments

Surgically transected medial collateral ligaments have also been studied.

  • Improved biomechanical strength
  • Improved functional recovery
  • Better microscopic tissue healing
  • Improved structural organization

Muscle

Severe muscle-transection and crush-injury models have shown recovery of both tissue structure and function.

  • Improved walking recovery
  • Greater load-to-failure strength
  • Muscle fibers bridging injured areas
  • Reduced muscle atrophy
  • Improved muscle regeneration markers

Bone

BPC-157 has been investigated in difficult bone-defect models.

  • Improved callus formation
  • Improved radiographic healing
  • Improved bone histomorphometry
  • Enhanced repair of segmental bone defects

Wounds

Early experimental work examined several core components of wound healing.

  • Increased granulation tissue
  • Enhanced collagen formation
  • Increased angiogenesis
  • Improved tensile strength
  • Improved wound closure biology

Tendon-to-Bone & Muscle-to-Tendon

Perhaps most interesting are injuries at the junction where two different tissues must reconnect.

  • Achilles tendon-to-bone reattachment
  • Myotendinous-junction repair
  • Improved collagen orientation
  • Improved functional recovery
  • Reduced progressive muscle atrophy

Important Evidence Distinction

These healing effects have primarily been demonstrated in animal models and laboratory studies. They should not be interpreted as proof that BPC-157 reliably heals these injuries in humans.

Tendon Healing: One of the Strongest Research Areas

Researchers have measured strength, collagen, structure, and function—not just inflammation

In transected rat Achilles tendons, untreated animals showed severely compromised healing.

BPC-157-treated animals demonstrated improvements across several different measures.

Achilles Tendon Transection

Researchers reported improvements in:

  • Load to failure: stronger repaired tendon
  • Elastic modulus: improved mechanical properties
  • Walking function: improved Achilles functional index
  • Collagen: increased and better-organized repair tissue
  • Fibroblasts: greater repair-cell activity
  • Defect size: smaller residual tendon gap

Fibroblast Migration

Tendon fibroblasts need to move into the damaged region before they can rebuild extracellular matrix.

Laboratory studies found BPC-157 increased tendon-fibroblast migration and spreading.

Cell Survival

Repair cells are exposed to oxidative and inflammatory stress after injury.

BPC-157 increased tendon-cell survival under experimentally induced oxidative stress.

Ligament & Muscle Repair

The research extends beyond tendon healing

Ligament Healing

In rats with completely transected medial collateral ligaments, BPC-157 was associated with better functional, biomechanical, macroscopic, and microscopic healing.

In plain language: the repaired ligaments looked better, functioned better, and tested stronger.

Muscle Healing

In a severe quadriceps-transection model, treated animals showed improved walking, increased mechanical strength, reconnection of muscle fibers across the injury, and markedly less atrophy.

Recovery was followed for more than two months.

BPC-157 research is not limited to “reducing soreness.” Investigators have repeatedly measured actual tissue reconstruction and restoration of function.

Repairing the Junction May Be Even More Interesting

Healing becomes more difficult where different tissue types have to reconnect

A tendon does not function by itself.

It must connect muscle to bone.

Injuries at these interfaces can be especially difficult because muscle, tendon, and bone have different cellular structures and mechanical demands.

Achilles Tendon-to-Bone Healing

In a rat model where the Achilles tendon was completely detached from the calcaneus, BPC-157-treated animals showed:

  • Improved functional recovery
  • Greater load-to-failure strength
  • Greater stiffness
  • Improved collagen type I organization
  • More advanced vascular development
  • Better microscopic tissue integration

Myotendinous Junction

In another difficult rat injury model involving separation of muscle from tendon, BPC-157 was associated with restoration of the junction and improved limb function.

  • Reduced defect size
  • Better-oriented repaired tissue
  • Reduced inflammatory infiltrate
  • Counteracted progressive muscle atrophy
  • Improved functional recovery

Bone Healing

BPC-157 has also been investigated in difficult bone-defect models

Bone healing requires far more than calcium.

New blood vessels must enter the injury. Osteogenic cells must proliferate and organize. A callus has to form. New matrix must mineralize. The tissue then has to remodel into functional bone.

Segmental Bone Defect

Researchers created a substantial segmental defect in rabbit radius bones—a defect that remained incompletely healed in controls.

BPC-157 significantly improved multiple measures of bone healing, including:

  • Callus surface
  • Radiographic healing
  • Bone-density measurements
  • Quantitative microscopic bone formation

How Might BPC-157 Support Tissue Repair?

Healing requires multiple systems to work in sequence
Injury
Vascular Response
Repair-Cell Migration
Collagen / Matrix Formation
Remodeling
Functional Tissue
1

Protect

Reduce cellular stress and help preserve repair-capable cells.

2

Perfuse

Support vascular signaling and blood-vessel development in injured tissue.

3

Rebuild

Promote fibroblast migration, collagen production, and extracellular-matrix formation.

4

Remodel

Organize newly formed tissue into stronger and more functional structure.

Fibroblast Migration: Getting the Builders to the Job Site

Repair cells cannot rebuild a tendon if they cannot reach the damaged area

Fibroblasts are central to connective-tissue healing.

They migrate into injured tissue and help produce collagen and extracellular matrix.

Laboratory research found that BPC-157 increased tendon-fibroblast migration and spreading in a dose-dependent fashion.

Researchers also observed activation of FAK and paxillin, proteins involved in cell adhesion and movement.

One way to think about BPC-157 is not simply “make more collagen.” First, the cells responsible for rebuilding tissue have to survive, migrate to the injury, attach, organize, and then create matrix.

Blood Flow & Angiogenesis

Damaged tissue cannot rebuild without oxygen and nutrients

Healing tissue requires a vascular supply.

New blood vessels deliver oxygen, amino acids, glucose, immune cells, and other substrates required for rebuilding.

Experimental BPC-157 research has repeatedly reported effects on vascular signaling and angiogenesis.

The peptide has also been linked experimentally to nitric-oxide signaling, which is involved in vascular tone, endothelial function, and repair biology.

Repair Requires Delivery

Collagen synthesis gets much of the attention, but tissue regeneration also depends on creating an environment capable of delivering the materials required to rebuild.

Wound Healing

Some of the earliest BPC-157 experiments examined the fundamental components of tissue repair

Researchers studied skin wounds, intestinal anastomoses, and experimental angiogenesis.

BPC-157 treatment was associated with improvements in:

Building New Tissue

Increased granulation tissue and collagen formation were observed in experimental wound models.

Building Blood Supply

Increased vascular formation was also observed, supporting the delivery system required for repair.

Gastrointestinal Repair & Protection

The gastrointestinal tract is where BPC-157 research originally developed

BPC-157 originated from research involving protective gastric peptides.

Experimental studies have investigated BPC-157 in gastric injury, intestinal injury, ulceration, inflammatory bowel models, intestinal anastomoses, and fistula healing.

The proposed effects overlap with its musculoskeletal repair biology:

vascular protection, collagen formation, wound closure, nitric oxide signaling, and restoration of damaged tissue architecture.

Why This Matters

The GI findings help explain why BPC-157 is viewed as a broader tissue-repair peptide rather than simply an orthopedic compound.

Why Is BPC-157 Discussed So Often in Recovery?

Because injury rarely involves only one biological pathway

A tendon injury is not simply “inflammation.”

A muscle tear is not simply “pain.”

A ligament sprain is not simply “swelling.”

Recovery requires multiple coordinated steps:

control excessive inflammatory damage, protect surviving cells, establish blood supply, recruit repair cells, synthesize collagen, rebuild extracellular matrix, organize tissue, restore mechanical strength, and gradually return that tissue to load.

BPC-157 Is Interesting Because It Appears to Touch Several Parts of the Repair Process

The experimental literature describes effects involving fibroblast migration, cellular survival, vascular signaling, collagen organization, connective-tissue strength, and functional recovery.

The goal is not merely less pain. The interesting question is whether damaged tissue can rebuild better.

Key Experimental Research

What investigators actually measured

Achilles Tendon Healing

Transected Achilles tendons treated with BPC-157 demonstrated improved mechanical strength, function, fibroblast formation, collagen deposition, and restoration of tendon integrity.

Tendon-to-Bone Reattachment

BPC-157 improved function, load-to-failure strength, stiffness, collagen type I organization, and vascular appearance following Achilles detachment from bone.

Ligament Healing

Transected medial collateral ligaments showed improved functional, biomechanical, macroscopic, and microscopic healing.

Muscle Healing

Completely transected quadriceps muscle demonstrated increased mechanical strength, restoration of walking function, muscle-fiber reconnection, and reduced atrophy.

Bone Defect Healing

Rabbit segmental bone defects showed improved callus development, radiographic healing, and quantitative bone formation.

Fibroblast Migration

Cell-culture work showed increased tendon-fibroblast migration, spreading, survival under oxidative stress, and activation of FAK-paxillin signaling.

Why People Become Interested in BPC-157

The research naturally generates interest around injuries where tissue quality matters

Tendinopathy

Achilles, patellar, rotator-cuff, elbow, and other tendon-related problems generate interest because of the tendon repair literature.

Ligament Injuries

Sprains and ligament damage attract interest because of the experimental ligament-healing findings.

Muscle Injury

Muscle strains, tears, and difficult muscle-tendon junction injuries are conceptually relevant to the animal research.

Post-Injury Recovery

The broader repair pathway is why BPC-157 is frequently discussed during rehabilitation and return-to-function conversations.

GI Integrity

Its gastric origins and intestinal-repair research explain interest in gastrointestinal tissue protection.

Complex Tissue Repair

Research involving wounds, tendon-to-bone attachment, and myotendinous junctions suggests interest beyond simple inflammation control.

These Are Areas of Research Interest—not Proven Human Indications

Animal results help define plausible applications for future human trials. They do not establish that BPC-157 treats a rotator cuff tear, tendonitis, ligament sprain, fracture, surgical wound, or gastrointestinal disease in an individual patient.

BPC-157 Should Still Be Viewed as Part of a Recovery System

Biology can support repair—but tissue still needs the conditions required to rebuild

A peptide cannot replace mechanical rehabilitation.

It cannot replace adequate protein.

It cannot correct poor circulation.

It cannot overcome repeated reinjury.

And it cannot replace the progressive loading that teaches repaired connective tissue how to tolerate force again.

Better repair biology may help create the tissue. Rehabilitation teaches that tissue what it needs to become.

Research & Regulatory Status

Important context—but not the entire story

BPC-157 remains investigational and is not FDA-approved for treatment of musculoskeletal injury, wound healing, gastrointestinal disease, or any other therapeutic indication.

Human efficacy evidence remains very limited compared with the extensive animal literature described above.

FDA PCAC Review — July 2026

BPC-157-related bulk drug substances were reviewed by the FDA’s Pharmacy Compounding Advisory Committee as part of the process for considering substances for the Section 503A Bulks List.

The use evaluated by FDA in that review was ulcerative colitis. An advisory-committee review is part of the regulatory process and is not FDA approval of BPC-157 as a drug.

Human Safety Data Remain Limited

FDA has specifically noted limited human safety information and concerns involving peptide characterization, impurities, and potential immunogenicity in compounded BPC-157 products.

Selected Scientific References

Experimental studies supporting the healing mechanisms discussed above
Staresinic M, et al. Journal of Orthopaedic Research. 2003.
Transected rat Achilles-tendon study demonstrating improvements in biomechanics, functional recovery, fibroblast formation, collagen, and tendon integrity.
View on PubMed →
Krivic A, et al. Journal of Orthopaedic Research. 2006.
Achilles tendon-to-bone detachment model showing improvements in function, load-to-failure strength, stiffness, collagen type I, and vascular development.
View on PubMed →
Cerovecki T, et al. Journal of Applied Physiology. 2010.
Laboratory study demonstrating enhanced tendon-fibroblast migration, spreading, cell survival under oxidative stress, and FAK-paxillin pathway activation.
View on PubMed →
Cerovecki T, et al. Journal of Orthopaedic Research. 2010.
Rat medial collateral ligament study showing improved functional, biomechanical, macroscopic, and histologic healing.
View on PubMed →
Staresinic M, et al. Journal of Orthopaedic Research. 2006.
Completely transected quadriceps muscle model showing restoration of function, greater mechanical strength, muscle-fiber regeneration, and attenuation of atrophy.
View on PubMed →
Sebecic B, et al. Bone. 1999.
Rabbit segmental bone-defect study demonstrating improved bone healing across radiographic and quantitative histologic measures.
View on PubMed →
Mikus D, et al. 1997.
Experimental wound-healing research examining collagen formation, angiogenesis, granulation tissue, and wound tensile strength.
View on PubMed →
FDA Pharmacy Compounding Advisory Committee. July 2026.
FDA materials concerning BPC-157-related bulk drug substances and consideration for the Section 503A Bulks List.
View FDA Materials →
Educational Disclaimer: BPC-157 is investigational and is not FDA-approved for treatment of tendon injury, ligament injury, muscle injury, bone injury, wound healing, gastrointestinal disease, or any other therapeutic indication. Much of the healing research discussed on this page comes from animal models or laboratory studies. Results in animals do not establish clinical effectiveness in humans. This page is intended to explain the available research and proposed biological mechanisms and is not a substitute for individualized medical evaluation or treatment.